Vets Now Ltd, the provider of out-of-hours emergency vet care has announced the acquisition of Salus Quality Partnerships (QP), a Health and Safety service provider to the veterinary profession in the UK.
Vets Now says this acquisition will extend the range of its services aimed at improving the quality of life within the profession and supporting practices to run more efficiently.
Vets Now currently runs 50 emergency clinics throughout the country including two referral hospitals in Scotland and the South West of England. In recent years Vets Now has extended its offering to the profession to include business services aimed at supporting vet practices. These services include Lifelearn (Client Education & Compliance), Staff Training Services, RCVS Practice Standards support and Practice Web services.
Salus QP, which has been running for over 18 years, offers veterinary practices information and services to help them comply with Health and Safety legislation and an anaesthetic monitoring service.
Richard Dixon, Founder of Vets Now said: "Our core purpose at Vets Now has always been to improve the lives of vets and pets, and the recent addition of Salus QP will help to do exactly that. The Salus QP team, led by Mark Enright and Alison Clark, have extensive knowledge in their field and crucially they fully understand the issues as they specifically apply to veterinary practices. With Salus QP our aim is to keep it simple and practical, helping practices fulfil their obligations without letting the Health and Safety tail wag the practice dog. I am very much looking forward to working with both Mark and Alison in the future as we take a fresh and common sense approach to Health and Safety in our profession."
Mark Enright said: "Salus QP and Vets Now both share a strong commitment to the veterinary profession and I truly believe that together we will be greater than the sum of our parts. I look forward to a future of innovations and benefits for all, and to continue to form quality partnerships within the veterinary profession."
The Disciplinary Committee had found Dr Schulze Allen guilty of four charges, namely that he had been convicted of the criminal offence of petty theft in the US which rendered him unfit to practise, and that on three subsequent occasions, twice to the RCVS and once to a notary in California, dishonestly represented that he had no criminal convictions.
Following the DC hearing, Dr Schulze Allen submitted an appeal to the Privy Council. The basis of his appeal revolved around whether, under Californian law, his conviction for petty theft was a conviction for a criminal offence or an infraction, and whether an infraction under US law was a criminal offence.
The RCVS had argued that while the theft is not a criminal felony in California, it would be considered so under English law.
However, the Board of the Privy Council which heard the appeal – comprising Lords Wilson, Carnwath and Lloyd-Jones, found the College had not proven beyond all reasonable doubt that Dr Schulze Allen was convicted of a criminal offence under Californian law. It therefore upheld his appeal against the DC’s finding that he had committed a criminal offence.
The Privy Council then considered Dr Schulze Allen’s appeal against the third and fourth of the charges against him - that he was dishonest in his representations to the College that he did not have a ‘criminal’ conviction and did not have a ‘criminal record’. The Privy Council found that, since the conviction for petty theft was an infraction, and was not a criminal offence and did not leave Dr Schulze Allen with a criminal record, then, strictly speaking, his representations to the RCVS were not false and so upheld his appeal against these two charges.
The Privy Council then considered Dr Schulze Allen’s appeal against the College’s second charge against him. This charge was that he had, in a written application for restoration to the Register, represented that he did not have any cautions, criminal convictions or "adverse findings". The College argued that he still had a responsibility to make a full and frank disclosure about his infraction, even if it did not meet the threshold of ‘criminal’ under Californian law.
The Board of the Privy Council said it had, on Dr Schulze Allen’s behalf, done its best to identify some argument that his conviction for a petty theft infraction did not amount to an "adverse finding", but failed. Rather, it found that "the conviction obviously amounted to an adverse finding."
The Board added that "there is no material by reference to which the Board [of the Privy Council] can depart from the [Disciplinary] Committee’s conclusion that, in answering “no” to that question, he knew that his answer was untrue. In other words, his denial was dishonest."
The Board therefore allowed the appeal against the DC’s conclusion on the first, third and fourth charges. But it dismissed the appeal against its conclusion on the second charge, namely that in that regard Dr Schulze Allen had been guilty of disgraceful conduct in a professional respect."
The Board then set aside the original sanction, that Dr Schulze Allen be removed from the Register, and tasked the Committee with identifying the appropriate sanction in relation to the second charge.
The Disciplinary Committee will now hold a further hearing to decide the sanction, at some time in the future. In the meantime Dr Schulze Allen remains on the Register of Veterinary Surgeons.
It is hoped the survey will capture the experiences vets have had reporting ADRs, as well as identifying barriers to the current process which could be used to improve the ease with which ADRs are reported in the future.
PhD student Heather Davies (pictured right), who is leading the research project, said: "The survey is an important opportunity to gain insights into the issues that vets face when dealing with ADRs.
"We want to make the process easier in order to improve the safety of veterinary medicines, and ultimately, we need the help of professionals on the front line in order to do that."
She added: "The survey is relatively short and can be completed anonymously.
"We’re really keen to gather as many of your experiences as possible so we’d like to encourage veterinary professionals to complete it."
The research is being carried out as part of a PhD project funded by the Veterinary Medicines Directorate (VMD) in collaboration with the Small Animal Veterinary Surveillance Network (SAVSNET), based at the university.
The survey is now open and you can take part here: https://liverpool.onlinesurveys.ac.uk/adrs-vet
Any questions about the survey can be addressed directly to the researchers: Heather Davies (PhD student): H.H.Davies@liverpool.ac.uk and/or Dr David Killick (Supervisor): David.Killick@liverpool.ac.uk.
The new product contains a combination of Omega-3s, toxin binders and antioxidants which the company claims flush out toxins, aid blood flow to the kidneys and maintain kidney architecture.
Matthew Shaw, Managing Director of nutravet said: "We’re really excited to launch nutraren, it’s a product our team have been working on for some time to make sure we have developed the best renal product for vets to recommend to their clients.
"Using independent trial data, we’ve been able to develop a unique formulation for nutraren containing 100% natural ingredients to benefit a pet’s long-term kidney health."
Authorised veterinary practices can now order nutraren from nutravet.
For more information, contact nutravet on 0845 604 1688, visit: www.nutravet.co.uk or email: info@nutravet.co.uk.
The rationale for completing a course of antibiotics has always been to prevent the growth of drug-resistant bacteria. However, the article says there is little evidence to support this idea, and that in fact, taking antibiotics for longer than necessary presents a greater risk of causing antibiotic resistance.
Responding to article, BVA Junior Vice President John Fishwick said: "We're very aware of the global threat antimicrobial resistance poses to human and animal health, and the UK veterinary profession is committed to the responsible use of antibiotics. Medicines should never be used to compensate for poor husbandry practices and routine habitual prophylactic use in healthy animals to prevent disease is a no-go.
"The article in the BMJ suggests that antibiotics should be used for as short a period as possible, and that we should move away from the concept of following a predetermined course. This may indeed be a very important advance, but it is far too early to determine how this would work in veterinary practice. We need to clearly establish the evidence supporting it.
"We support the researchers’ calls for clinical trials to determine the most effective strategies for antibiotic treatment. Until further studies are conducted, it is too early to change the way we prescribe medicines and vets should continue to prescribe as previously, only when necessary. It is also vital that clients continue to follow the directions given by their vets, both in terms of dosage and duration of treatment, carefully."
The BVA is also calling on Government to tighten pet import rules.
The advice follows news about a positive Brucella canis test in a rescue dog imported from Belarus in March this year.
The woman fostering the dog was hospitalised after coming into close contact with it, in the UK’s first confirmed dog-to-human transmission.
The foster animal and four pet dogs who were exposed to the disease, three of whom also tested positive, all had to be euthanised.
Data released by the Government shows a steep rise in confirmed Brucella canis cases since the start of 2020, rising from just three before that year to 107 till July this year.
The dogs were all either imported, had returned from holiday overseas, or been bred with an imported dog.
BVA is asking veterinary teams to:
British Veterinary Association President Justine Shotton said: “This recent case of Brucella canis in a foster dog is extremely tragic and highlights why vets have long raised concerns over the real and serious risks of importing ‘Trojan’ rescue dogs with unknown health histories into the UK.
“We know there is an added public health risk too, including for veterinary teams who treat and handle these animals, from contact with an infected dog’s contaminated body tissues and fluids.
"BVA continues to call on the Government to take urgent action to introduce stricter pet import measures, including mandatory pre-import testing, so we can minimise the spread of Brucella canis and other emerging diseases.
"We are also calling for the strengthening of enforcement provisions and checks on dogs brought into the country through the commercial route."
The 2021 B. canis risk view and statement by Public Health England (now UK Health Security Agency) contains vital information and recommendations for veterinary professionals: here:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960013/20210210_Brucella_canis_statement.pdf
BVA’s recommendations on tightening pet travel legislation: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Companion_animals/BVA%20Position%20on%20Pet%20Travel%20Full.pdf
The first is that the College will allow veterinary surgeons and nurses to carry over some of the CPD hours they have accrued in 2019 into 2020, to smoothen the transition to an annual hourly requirement.
Vets will be allowed to carry over 25 hours and VNs 10 hours of accumulated CPD from 2019 through to 2020.
This will apply once, in 2020 only, and is only applicable to vets and VNs who have been CPD-compliant from 2017 to 2019 and have a surplus number of hours to carry over.
Secondly, the College is going to allow vets and VNs to take a six-month 'CPD pause' for planned periods away from work, such as parental leave, and exceptional circumstances, such as serious ill health or unforeseen changes to family responsibilities, without the need to make up the hours when they return to work. This will reduce the burden on vets and VNs returning to work after a break.
RCVS Director of Education, Dr Linda Prescott-Clements said: "We hope that these changes to the CPD policy will support vets and VNs to make the transition to an annual hourly requirement.
"We received a sample of feedback from some members of the veterinary professions regarding the move to annual hourly CPD requirements and these additions have been introduced support members during this transition and to mitigate some of the concerns raised."
For more information about the CPD requirement for both vets and vet nurses, what activities might count as CPD, how to record your CPD and a series of frequently asked questions about CPD please visit our dedicated page: www.rcvs.org.uk/cpd.
Zoetis has announced the launch of Simparica, a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age.
The company says the new product, which comes in the form of a tasty chewable tablet, acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month.
Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs.² It starts to kill fleas quickly within three hours³ and continues to kill fleas for at least 35 days², making it suitable as part of a treatment strategy for Flea Allergic Dermatitis.
The product also protects dogs against infestations with the most common ticks found to infest dogs in Europe2,4, including Dermacentor reticulatus, the species associated with the disease babesiosis, which has recently been reported in the UK. It’s also the only treatment for Ixodes hexagonus, one of the most prevalent ticks in the UK. The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and over 96% are killed within 24 hours.4
Zoetis says Simparica is also effective against Rhipicephalus sanguineus, and Sarcoptes scabiei, and that laboratory evidence shows efficacy for Demodex Canis and Otodectes Cynotis.
Zoetis believes that Simparica’s ability to provide continuous protection up to and beyond the monthly treatment period is very important for pet owners. Sixty three per cent of owners confess to giving flea and tick treatment later than when it was due, with the median being 5 days late.¹ Simparica gives vets and forgetful pet owners the peace of mind of extended duration of activity helping to minimise the potential risk of protection gaps.
Ned Flaxman, companion animal business unit director at Zoetis said: "With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and pet owner satisfaction. The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps vets and dog owners minimise the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for at least 35 days without losing efficacy — well beyond the monthly treatment period.
"With its rapid onset, robust duration of activity and very good safety profile, Simparica is the only oral isoxazoline indicated for four species of ticks in Europe including Ixodes hexagonus and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration."
For more information please speak to your account manager or contact customer support on 0854 300 8034.
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 3rd April 2019.
Matt Baker, presenter of The One Show and Countryfile, will be hosting the Ceva Animal Welfare Awards alongside the head judge, Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.
The award categories include:
Chris Laurence Vet of the Year – sponsored by Vet Record
Vet Nurse of the Year – sponsored by Agria Pet Insurance
Charity Team of the Year – sponsored by PDSA
Charitable Contribution of the Year – sponsored by Blue Cross
International Cat Care Welfare of the Year – sponsored by International Cat Care
Farmer of the Year – sponsored by R.A.B.I.
Farm Educator of the Year – sponsored by NADIS
Outstanding Contribution to Animal Welfare – sponsored by Your Dog and Your Cat magazines
To nominate someone for an award, visit www.cevawelfareawards.com. They can come from all walks of life and will be assessed on the evidence provided in the original nomination.
Entries must be in by Friday 25 January 2019.
The survey was conducted by Mo Gannon & Associates, which asked 2,000 UK adults about their satisfaction with the service they and their animals received from veterinary surgeons, levels of trust in the profession, and whether the service provided by vets represents value for money.
32% of the respondents felt that veterinary surgeons represented excellent (8%) or good (24%) value for money. 38% thought that veterinary fees are fair. However, 29% thought that veterinary surgeons and their services provided poor (21%) or very poor (8%) value for money. The results were very similar to the last time the survey was conducted, in 2015.
Nevertheless, veterinary surgeons continue to enjoy very high levels of trust amongst the public. 94% said they either completely trust (34%) or generally trust (60%) vets. This put veterinary surgeons in third place amongst the most trusted professions, below opticians and pharmacists but above GPs and and dentists.
Satisfaction with the profession was also high. 80% said they were either very satisfied (39%) or satisfied (41%), putting vets in fourth place below opticians, pharmacists and dentists, but above general practitioners and accountants.
RCVS President Dr Niall Connell, pictured right (would you trust this man?) said: "These results clearly demonstrate that there is a great deal of good will towards the veterinary profession and the work they do in treating the nation’s animals and serving their communities. The basis of all good relationships is trust, and it is fantastic to see that our clients continue overwhelmingly to trust our knowledge and expertise and remain very happy with the service we provide them.
"The picture on value for money is clearly a bit more mixed, although clearly 70% of the respondents recognise that we at least charge fair fees in terms of our time and expertise. There is, of course, always more work that we can do in order to help the public understand veterinary costs and fees and promote the value of veterinary care, as demonstrated by last year’s joint Pets Need Vets social media campaign with BVA, in which we highlighted the benefits to pet owners of being registered with a vet."
A 2012 RVC graduate, Daniella is the Principle Exotics Vet at ParkVet Hospital and is studying towards a certificate in Zoological Medicine. She said: "Despite their amazing work, the AWF struggles for funds to continue its vital work, so I have decided not only to be the first ever person to run the London Marathon for the AWF, but to run it in costume!
"Those who know me will be aware that running is not among my favourite activities, but I am stepping up to the challenge to raise much-needed funds for this fantastic charity that’s making a real, tangible difference to animals worldwide."
"Working full time in clinical practice, including being part of an out-of-hours rota, means training must be factored in with military precision: so far, some of my longer runs are planned for 4 am!
"I also entered the Hastings Half Marathon on 18 March, and my final training run prior to the big day is scheduled for when I will be in Queensland, Australia for my brother’s wedding.
"If I can manage 22 miles in those hot and humid conditions, the London Marathon should be a breeze!”
Chris Laurence. AWF Chair of Trustees, said: "I am delighted that Daniella has chosen to raise funds for AWF in what is arguably one of the biggest sporting events in the world. On behalf of the organisation, I’d like to thank her for her support and wish her all the best for the marathon."
To support Daniella’s fundraising, visit: https://uk.virginmoneygiving.com/DaniellaDosSantos
For updates on her training and to find out more about AWF, visit www.bva-awf.org.uk
Pergocoat contains pergolide, a long-acting dopamine receptor agonist.
It is available in 0.5mg (off-white) and 1mg (yellow) tablets for accurate dosing without the need to split tablets.
The tablets are film-coated to mask the bitter taste of pergolide and create a barrier between the horse owner and the active ingredient.
Available in two different pack sizes containing 60 or 160 tablets, Pergocoat tablets are packaged in double layered blister packs to help minimise the risk of accidental ingestion.
Rachel Addison BVM&S MRCVS, equine field support manager at Dechra said: “Pergocoat is available in two convenient tablet sizes to achieve an optimal treatment response.
"Horses can be monitored and reviewed every four to six weeks until stabilisation or improvement of clinical signs is observed.”
https://www.dechra.co.uk/products/horse/prescription/pergocoat#Pergocoat-0-5mg-60-film-coated-tablets-for-horses.
The extension includes a new diagnostic imaging suite with both CT and MRI scanners, a fourth operating theatre, two more consulting rooms, an additional ward for dogs and an expanded office for clinicians.
North Downs hospital director Terry Emmerson said: "This significant investment illustrates our commitment to providing the highest standards of medical and surgical care for our pets in a caring, compassionate environment.
"It has provided us with a number of important new facilities, allowing us to continue to build on our services and our level of care.
As part of the expansion, North Downs has also recruited five more clinicians, two specialising in small animal surgery, one in neurology, one in ophthalmology and one in anaesthesia.
Mr Emmerson said: "All the investment in facilities and technology is very important and exciting but we also recognised the need to invest in recruiting more talented staff to help us make the most of it all.
"That’s why we have added five new clinicians in several key disciplines and in turn increased the size of our clinicians’ office to help incorporate those additional staff.
"It all means we can now offer an even better service, leading facilities and treatment within a far more structured and organised layout which helps makes everything more efficient and user-friendly for staff and patients."
For more information about North Downs Specialist Referrals, visit www.ndsr.co.uk.
Petplan Equine has announced the finalists for the fifth annual Petplan Equine Vet of the Year Award.
The winner of the award award, which is sponsored by Petplan Equine in association with Horse & Rider magazine, will be announced at the annual Animal Health Trust Equestrian Awards, being held at London's Lancaster Hotel on Thursday 1st November, 2012.
The finalists are:
Jess Hill BVM&S MRCVS Woodlands Veterinary Clinic, Cheltenham, Glos, EnglandJess, who qualified in 2003 at the University of Edinburgh Royal (Dick) School for Veterinary Studies, is described as simply "brilliant" for her outstanding calm, capable and kind approach to her work and the way in which she makes herself readily available to her clients. One nomination typifies all those received in praise of Jess' work: "She is incredibly knowledgeable and dedicated and nothing is too much trouble. She is great with horses - always quiet, kind and gentle. She works quickly and confidently, doesn't suggest unnecessary expensive procedures and is always cheerful and a pleasure to be with."
Keith Chandler BVMS Cert EP MRCVS, Kessock Equine Vets, Inverness, ScotlandKeith Chandler, a senior partner at Kessock Equine Vets received several nominations which credited not only him personally for his dedication, knowledge, pragmatic and caring approach but also his practice for its outstanding customer service. Upon receiving news of his nomination, Keith was swift to praise his team and explained: "This nomination reflects the exceptional team I have around me - together we strive to offer continuity, consistency and a minimum level of care to all our clients irrespective of which vet is in attendance."
Lee Paul, BSC BVM&S Cert EP MRCVS, Bushy Equine, Gwaelod-y-Garth, WalesNominations for Lee Paul, a specialist in internal and stud medicine who qualified at Edinburgh University's Royal Dick Veterinary School in 2002, unanimously praised his willingness to 'never give up' and to go beyond the call of duty. He is said to be highly dedicated and is praised for his willingness to always be available such as on the occasion when a horse he had been treating for a swelling in her throat presented complications during a weekend when he was not on duty. Despite this Lee, who had been contacted by the duty vet for background information, attended the call himself within an hour complete with the stethoscope he'd collected from the surgery en route and with his family in his car!
This year's judges were David Stickles, Head of Fund Raising at the Animal Health Trust, Alison Bridge, Editor of Horse & Rider magazine, Ben Mayes, President of the British Equine Veterinary Association (BEVA) and Gil Riley, 2009 Petplan Equine Vet of the Year.
Petplan says that the record number of high calibre nominations made it hard for the judges to choose three finalists. Isabella Von Mesterhazy, Head of Marketing for Petplan Equine said: "Anyone motivated to nominate their vet for this award must hold them in extremely high regard so once again we were very impressed by both the quality and quantity of nominations we received. It is heartwarming and inspiring to read the submissions that describe the outstanding contributions made by all the nominees in keeping owners happy and horses healthy. It has not been easy to select just three to go through to the final."
The winner will be posted on www.petplanequine.co.uk on Friday 2 of November.
The new, four storey, architecturally-designed clinic is full of natural light and includes calming and spacious staff breakout areas.
By combining a beautiful work environment with seamless technology, the company believes it can transform working conditions and job satisfaction for vet teams.
On the tech side, the Creature Comforts has created a proprietary app which allows triage to be handled online and for staff to work flexibly.
The company says the app also reduces the administrative burden, a contributory factor for staff burnout.
Creature Comforts says most clients subscribe at a cost of £20 per pet per month, giving them unlimited consultations, instant bookings and live chat via the app (as well as annual vaccinations and discounted routine treatments).
This should mean animals are seen more frequently, and conditions can be identified and treated earlier.
Memberships will be capped to control vet team caseload and to ensure a good customer experience.
The company is also addressing Competition and Markets Authority concerns, with prices for routine treatments listed on its website, upfront estimates for procedures, and a business model hinged on unlimited access to expertise (i.e. consultations, instant in-app bookings and live chat) at no extra cost for subscribed members.
Creature Comforts says its vet team benefits from a share of their clinic’s profits, above industry-standard pay, compensated overtime, a well-balanced staffing ratio, manageable working hours and scheduled breaks.
Dr Russell Welsh, COO and co-founder of Creature Comforts, said: “It’s an incredible feeling to see a plan come together in a sector that’s so ripe for transformation.
"We want to bring the passion, joy and fun back to our profession, and this is an opportunity to do things differently and vastly better, with a fresh and carefully-considered business model founded on the principles of health and happiness.
"This is vet care as it should be."
https://www.creaturecomforts.co.uk
"We would like to reassure vets, and through them dog owners, that we are constantly reviewing adverse event report data to ensure that the benefits of each UK licenced veterinary medicine product outweighs the risk posed by their potential side-effects.
There are a number of vaccines authorised in the UK containing either two (L2) or four (L4) strains of Leptospira. Based on the most recent periodic safety update report data received for each product, the incidence of adverse animal reactions for all L2 vaccine products combined is 0.015%; for L4 vaccine products this figure is 0.069%.
In other words, the VMD has received fewer than 2 adverse reactions for L2, and fewer than 7 for L4, for every 10,000 doses sold. This includes every suspected adverse event reported, even cases that were considered unclassifiable or were later found to be unrelated to the vaccine.
The overall incidence of suspected adverse reactions for both L2 and L4 vaccine products is therefore considered to be rare."
Norbrook Laboratories has launched a long-acting cattle bolus which it says will reduce the risk of Milk Fever.
According to the company, Calcitrace D3 is the first and only long-acting bolus to offer slow and fast releasing calcium to provide sustained calcium levels for 48 to 72 hours. In addition, Calcitrace D3 provides Magnesium, Phosphate and Vitamin D3 making it the most comprehensive bolus available.
Calcitrace D3 is smooth gelatin coated bolus with a rounded tip designed for easier administration. Norbrook says it is smaller than other boluses making it less likely to cause trauma on the orpharynx during administration.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Milk Fever is a common metabolic disorder in dairy cattle which generally affects older, high producing cows and is caused by a rapid decrease in calcium concentrations in the blood just before calving. It is estimated that 3-10% of cows are affected by Milk Fever with a cost of more than £200 per incident so it is crucial that farmers and vets reduce the risk as effectively as possible.
"Norbrook's new Calcitrace D3 bolus which should be administered just before calving, provides higher calcium blood levels during the critical 12 - 48 hour post calving period and provides sustained increased levels for well beyond 48 hours. With the addition of Magnesium, Phosphate and Vitamin D3, Calcitrace D3 provides additional protection against Milk Fever."
Andrew Hillan MVB MRCVS, Director of Veterinary Sciences at Norbrook, led the development of Calcitrace D3. He said: "The launch of Calcitrace D3 is another illustration of the very high quality of technical expertise that exists within our research and development department and underlines Norbrook's commitment to developing high quality and innovative products. It comes from a strong and exciting pipeline of new products which we will bring to the market over the next couple of years."
The company says that practices transferring to its pet health plan portal will be able to take greater control of their pet health plans and benefit from a range of innovative services for the same cost. They include the VMD-approved Post2Pet home delivery service, a messaging system to advise clients on applying products, attending appointments or renewing prescriptions, reporting to give practice leaders the insights they need to drive plan performance, the ability for pet owners to sign up online rather than visit the practice, and 24/7 access to a marketing hub and the Premier Vet Alliance Learning Academy.
Premier Vet Alliance’s Business Development Director Andy Taylor said: "We are excited to be offering our high performing Premier Pet Care Plan to the many new practices joining us following our acquisition of Simplyhealth’s animal health business.
"We are working to make the transition seamless and believe that our new customers will be delighted at the expanded range of functionality our portal offers them, together with the reduced administrative burden. We will continue to invest in its development to ensure that all of our customers can be sure that their pet health plan offers the most powerful set of tools and services available to help them drive up the profitability of their practice, while offering gold standard care to their patients and peace of mind to their clients."
For more information, visit: https://premiervetalliance.com/uk/
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
The publishers say that many people who prescribe veterinary medicines or who handle them (or bodily fluids that may contain them or their active metabolites) are not aware of the potential harmful effects they can have on human reproduction.
'Handling Veterinary Medicines and Pregnancy' gives up-to-date, evidence-based guidance on which drugs and methods of handling are hazardous; information on the relevant regulations relating to the safe handling of such medicines; and practical guidance on avoiding harm in veterinary practice.
Veterinary Prescriber says that once you have completed the module, you will:
understand the principles of reproductive toxicity
understand how data on the harmful effects of medicines are generated
be aware of the evidence on reproductive harm in veterinary practice
understand what practical measures to take to avoid harm
know where to find helpful information on medicines and pregnancy
For more information, visit: https://www.veterinaryprescriber.org/subscribers/
The service uses an Xstrahl 100 superficial radiotherapy system, a £150,000 piece of equipment installed by Paragon after it was used successfully in the USA by the hospital's medical and radiation oncology specialist, Dr Rodney Ayl.
Rodney (pictured right) says the new equipment will transform the way Paragon can treat skin cancers, dermatological disorders and some other common superficial conditions.
He said: “This is a very exciting development for us and our clients because Xstrahl systems have been used so successfully in human medicine for many years.
“This prompted us to explore adapting the SRT system for veterinary use in the UK and we hope to collaborate with Colorado State University, which has a similar unit, to develop protocols for pets.
“We believe this will be a significant advance in the treatment and care of animals and we’re delighted to be at the forefront of introducing this new service.
“It is the only one of its kind for pets in the UK and there are very few units like this anywhere in the veterinary industry, so it really is an important move forward.”
Xstrahl radiotherapy systems were originally designed for the treatment of skin cancer, dermatological disorders, certain types of benign disease and some palliative care in humans.
Rodney says that having adapted the SRT system for animals will transform their treatment and the logistics and cost of getting radiation therapy for superficial skin conditions.
He added: “Superficial radiotherapy is particularly useful for treating some types of skin cancer where it may be preferable to surgery as it can deliver excellent non-invasive outcomes with curative or palliative intent.
“The treatment is less stressful from the outset and, thanks to its mechanism of action, it is also pain-free.
“Its use of different size cones, directly over the lesion, minimises effects on healthy skin and the fast treatment means a large reduction in time and impact on the patient’s day-to-day life, while providing a highly-effective treatment.
“The machine’s flexibility also makes it particularly suited for treating multiple lesions that are difficult to access, such as the head and neck, without changing patient positioning.
“The Xstrahl 100 system will help us to respond to the growing demand for radiation treatment and we can treat these patients on an outpatient basis, helping us to reduce surgical and hospitalisation costs.
“The technology is a real winner. It is easy to use and helps us to deliver safe and effective radiotherapy to our animal patients.
“It provides a quicker, easier, cheaper and non-invasive alternative for superficial tumours, especially in geriatric patients where surgery is not always an option. We’re looking forward to seeing the positive results here at Paragon.”
For more information, visit www.paragonreferrals.co.uk.
The plans developed by the Animal and Plant Health Agency (APHA), an agency of the Department for Environment, Food & Rural Affairs (DEFRA), involved the creation of a new role of Certification Support Officers (CSOs), non-veterinarians who would support the work of Official Veterinarians (OVs) in the signing of export health certificates for products of animal origin such as meat, dairy, processed products and animal by-products.
The proposals for the creation of CSOs by APHA has arisen due to concerns about the growth of exports in recent years and the potential for an up to 300% increase in products requiring OV certification if the UK has to certify exports of products of animal origin to the EU once the UK leaves the EU. Under APHA’s plans CSOs will work under the direction of veterinary surgeons and support their certification work (for example, verifying temperature checks), although the final certification will always need to be signed by OVs. The role will not involve certification relating to live animals or germinal products.
At the RCVS Council meeting on Thursday 1 November 2018 Council members agreed to facilitate APHA’s proposals and to make changes to the RCVS requirements so as to allow CSOs to support OVs in their certification work.
Amanda Boag, RCVS President, said: "As we have stated in our recent statement on ‘no-deal’ Brexit, it has been estimated that there would be 325% increase in veterinary certification requirements if the UK leaves the EU without a deal, and with these proposals Defra and APHA are preparing for this by increasing the support available for Official Veterinarians. Furthermore the proposal is in line with the concept of a vet-led team, with veterinary surgeons focusing on tasks only vets can do, whilst delegating some tasks to suitably trained and quality-assured members of our teams.
"We appreciate that there were some concerns over the level of education and training required by CSOs and are glad that the APHA has accommodated those views by increasing the level of education to three A-Levels (or equivalent in Scotland) and clarifying the nature of the training required by CSOs.
"By signalling its support for the proposals, RCVS Council has been assured that the integrity and value of the veterinary signature will be upheld and we are glad that we can play a key role in helping the veterinary profession prepare the UK for leaving the EU."
The RCVS position statement on the potential impact of a ‘no-deal’ Brexit scenario is available at www.rcvs.org.uk/brexit
Bayer Animal Health has launched four short youtube films about parasites, fronted by celebrity veterinary surgeon, Scott Miller.
The press blurb says the films "will provide pet owners with an amazing and educational journey into the world of parasites and highlight the need for the control of these often unwelcome pests", which I would normally translate as: "will provide anyone with too much time on their hands with a rather dull five minute advertisement for our flea treatment".
But no. The big surprise is that in addition to the slick production values, these films actually are rather interesting. I've just watched the first, and learned a bit about the vampire bat. There's some compelling infra-red footage of some of them feeding on a sleeping horse.
Elsewhere in the You Tube clips, Scott discusses other parasites including fleas, ticks and worms, and shows the harm they can inflict if owners don't sufficiently protect their cats and dogs with appropriate treatments. On that score, he urges owners to seek veterinary advice. Scott also discusses the threats posed by the increasing urbanisation of foxes and by exotic diseases that are now being found much further north as a result of climate change.
Matt Frost, UK marketing manager at Bayer Animal Health, says: "The clips, all of which are around four minutes in length, provide an opportunity for pet owners to learn more about parasites in a novel and entertaining way. We hope that viewers will learn more about the inherent dangers some of these creatures pose to pets and the steps that can be taken to protect against them.
The other clips can be viewed online at www.youtube.com/user/parasitesundercover1. You might even like to embed them from youtube into your own practice website.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
The trial, which was conducted by a UK-French team of researchers from PBD Biotech and Biosellal, is being presented at the European Association of Veterinary Laboratory Diagnosticians (EAVLD) Congress in Brussels today.
Current tests only allow the reliable detection of Mycobacterium avium subspecies paratuberculosis (MAP) from 18-24 month calves and are unable to distinguish between active and passive infection.
For the 16-month trial, calves from three different herds and born from MAP-positive and MAP-negative cows were tested monthly using PBD Biotech’s Actiphage Rapid kit and Biosellal’s Bio-T kit MAP PCR on blood samples, and the same PCR on faeces.
Researchers say the trial proves that early detection of live MAP infection is possible, and paves the way for improved Johne’s disease monitoring and control measures on farms.
Co-Author Dr Ben Swift, Research Fellow in Antimicrobial Resistance at the Royal Veterinary College and R&D Director at PBD Biotech, said: "Young animals are highly susceptible to infection and being able to identify Johne’s disease at this early stage is key to controlling disease spread.
The trial showed that the sensitivity and specificity of Actiphage enables detection of lower levels of MAP than the current culture methods, and provides results in 6 hours rather than weeks."
The Actiphage Rapid technology used in the trial identified live MAP infection at least 4 weeks’ earlier than the faecal PCR in 75% of cases: in one case, the new diagnostic detected MAP in the blood of a one-day old calf born from a MAP-positive cow.
Claire Pelletier, Directrice Générale of BioDev, consultant to Biosellal, will be presenting findings from the trial, which also showed the transient nature of the infection. She said: "The study showed that two calves, identified as MAP-positive by Actiphage-PCR on blood during the first monthly sampling didn’t shed MAP into their faeces until 10 and 11 months. This emphasises that early detection provides a short window of time that allow for control of the disease."
Other international trials using Actiphage are underway to investigate the presence of MAP in milk.